Get a Deep Insight into the Hormone Replacement Therapies and Other Hormone Therapies: Global Markets

NEW YORK--(BUSINESS WIRE)--Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.

Hormone Replacement Therapies and Other Hormone Therapies: Global Markets

http://www.reportlinker.com/p096601/Hormone-Replacement-Therapies -and-Other-Hormone-Therapies-Global-Markets.html

(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

BCC’s goal in conducting this study is to provide an overview of the current and potential global market for hormone replacement therapy and other hormone therapies. The report determines the market size, market leaders, and factors affecting the market of hormone therapies.

The overview of types of diseases and different hormone therapies is also examined along with sale figures over the five-year period from 2008 to 2013. Companies that manufacture and sell hormonal drugs to treat various types of diseases are profiled, and the factors affecting markets for these products and how those markets are likely to change are analyzed. Revenues have been broken down by type of therapy and by region.

The key objective of this report is to present a comprehensive analysis of the current market and the future direction of hormone replacement and other hormonal therapies with an emphasis on new developments.

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY

INFORMATION SOURCES

ANALYST’S CREDENTIALS

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY TABLE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES, THROUGH 2013 ($ MILLIONS)

SUMMARY FIGURE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES, 2006-2013 ($ MILLIONS)

CHAPTER THREE: OVERVIEW

HORMONES

DEFINITIONS

Hormone

Peptide

Metabolism

INTRODUCTION

Classification of Hormones

Anatomical Source of the Hormone

Hypothalamic Hormones

Posterior Pituitary Hormone

Anterior Pituitary Hormone

Thyroid Hormones

Parathyroid Hormones

Cardiac Hormones

Adrenal Cortical Hormones

Adrenal Medullary Hormones

Kidney Hormones

Pancreatic Hormones

Liver Hormones

Digestive Hormones

Gonadal Hormones

Gonadal Hormones ()

Pineal Hormones

TABLE 1 ANATOMICAL CLASSIFICATION OF HORMONES

Chemical Classification

Peptide Hormones

Amine hormones

Steroid Hormones

TABLE 2 CHEMICAL CLASSIFICATION OF HORMONES

HORMONE THERAPY

DEFINITION

CHAPTER FOUR: CLASSIFICATION OF HORMONE THERAPY

ESTROGEN THERAPY

TABLE 3 DRUG PRODUCTS USED IN ESTROGEN THERAPY

PROGESTERONE/ESTROGEN THERAPY

TABLE 4 DRUG PRODUCTS USED IN ESTROGEN/PROGESTERONE COMBINATION THERAPY

PROGESTERONE THERAPY

TABLE 5 DRUG PRODUCTS USED IN PROGESTERONE THERAPY

RECOMBINANT GROWTH HORMONE THERAPY

TABLE 6 DRUG PRODUCTS USED IN RECOMBINANT GROWTH HORMONES

THYROID HORMONE THERAPY

TABLE 7 DRUG PRODUCTS USED IN THYROID HORMONE THERAPY

TESTOSTERONE REPLACEMENT THERAPY

TABLE 8 DRUG PRODUCTS USED IN TESTOSTERONE REPLACEMENT THERAPY

SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)

TABLE 9 DRUG PRODUCTS USED IN SELECTIVE ESTROGEN RECEPTOR MODULATORS

ANTIESTROGEN THERAPY

TABLE 10 DRUG PRODUCTS USED IN ANTIESTROGENS

ANTIANDROGEN THERAPY

TABLE 11 DRUG PRODUCTS USED IN ANTIANDROGEN THERAPY

AROMATASE INHIBITOR THERAPY

TABLE 12 DRUG PRODUCTS USED IN AROMATASE INHIBITOR THERAPY

LUTEINIZING HORMONE-RELEASING HORMONE

TABLE 13 DRUG PRODUCTS USED AS LUTEINIZING HORMONERELEASING HORMONE (LH RH)

CHAPTER FIVE: HORMONE THERAPY IN VARIOUS CONDITIONS

MENOPAUSE

MENOPAUSE AND HORMONE THERAPY

OSTEOPOROSIS

OSTEOPOROSIS AND HORMONE THERAPY

CANCER

CANCER AND HORMONE THERAPY

GROWTH HORMONE DEFICIENCIES

GROWTH HORMONE DEFICIENCY AND HORMONE THERAPY

TURNER’S SYNDROME

TURNER’S SYNDROME AND HORMONE THERAPY

KLINEFELTER SYNDROME

KLINEFELTER SYNDROME AND HORMONE THERAPY

THYROID HORMONE DISORDER: HYPOTHYROIDISM

HYPOTHYROIDISM AND HORMONE THERAPY

MALE HYPOGONADISM

MALE HYPOGONADISM AND HORMONE THERAPY

NOONAN SYNDROME

NOONAN SYNDROME AND HORMONE THERAPY

SHORT BOWEL SYNDROME (SBS)

SBS AND HORMONE THERAPY

PRADER-WILLI SYNDROME

PRADER-WILLI SYNDROME AND HORMONE THERAPY

GOITER

GOITER AND HORMONE THERAPY

CHAPTER SIX: REGULATORY ISSUES

NEW DRUG APPROVALS

TABLE 14 HORMONE THERAPY DRUGS APPROVED BY FDA (2005

TO JUNE 2008)

ALL TYPES OF APPROVALS

TABLE 15 HORMONE THERAPY ALL TYPES OF APPROVALS BY FDA (2005 TO JUNE 2008)

NEW DRUG APPLICATIONS

TABLE 16 NEW DRUG APPLICATIONS (2005 TO JUNE 2008)

RECALLS AND SAFETY ALERTS

TABLE 17 RECALLS AND SAFETY ALERTS (2005 TO JUNE 2008)

CHAPTER SEVEN: INDUSTRY STRUCTURE

ESTROGEN REPLACEMENT THERAPY

ESTROGEN (ALONE)

TABLE 18 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN (ALONE) THERAPY, 2007 (%)

FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN REPLACEMENT THERAPY, 2007 (%)

ESTROGEN/PROGESTERONE

TABLE 19 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/ PROGESTERONE) THERAPY, 2007(%)

FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/ PROGESTERONE) THERAPY, 2007 (%)

RECOMBINANT GROWTH HORMONE THERAPY

TABLE 20 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%)

FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%)

THYROID HORMONE THERAPY

TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%)

FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%)

TESTOSTERONE HORMONE THERAPY

TABLE 22 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%)

FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%)

ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)

TABLE 23 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%)

FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%)

ANTIANDROGENS

TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)

FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)

AROMATASE INHIBITORS

TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)

FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)

LUTEINIZING HORMONE RELEASING HORMONE (LHRH)

AGONISTS

TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)

FIGURE 9 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)

CHAPTER EIGHT: DEMAND AND USE

KEY MARKET RESTRAINTS

COMPETITION

PATENT EXPIRATION

TABLE 27 SIGNIFICANT PATENT EXPIRIES

COST OF HRT DRUGS

LOW AWARENESS

KEY MARKET DRIVERS

NEW DRUG DELIVERY TECHNOLOGIES

GROWING AWARENESS

AGING OF THE POPULATION

RETURNING CONFIDENCE IN HRT

BENEFITS OF HRT OVER NON-HORMONAL DRUGS

LIFE EXPECTANCY

DTC (DIRECT TO CONSUMER) ADVERTISING

STRATEGIES OF MANUFACTURERS

Strategies of Manufacturers ()

CHAPTER NINE: MARKET ANALYSIS

MARKET SIZE

TABLE 28 WORLDWIDE SALES OF HORMONE THERAPIES,THROUGH 2013 ($ MILLIONS)

FIGURE 10 WORLDWIDE SALES OF HORMONE THERAPIES, 2006-2013 ($ MILLIONS)

TABLE 29 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007

FIGURE 11 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007(%)

ESTROGEN REPLACEMENT THERAPY

Market Outlook

ESTROGEN

Market Size

TABLE 30 GLOBAL SALES OF ESTROGEN (ALONE) THERAPY,THROUGH 2013 ($ MILLIONS)

2006-2013 ($ MILLIONS)

COMBINATION THERAPY (ESTROGEN/ PROGESTERONE)

Market Size

TABLE 31 GLOBAL SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), THROUGH 2013 ($ MILLIONS)

FIGURE 13 WORLDWIDE SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), 2006-2013 ($ MILLIONS)

RECOMBINANT GROWTH HORMONE THERAPY

Market Outlook

Market Size

TABLE 32 GLOBAL SALES OF RECOBINANT GROWTH HORMONE THERAPY THROUGH 2013 ($ MILLIONS)

FIGURE 14 WORLDWIDE SALES OF RECOMBINANT GROWTH HORMONE THERAPY, 2006-2013 ($ MILLIONS)

THYROID HORMONE THERAPY

Market Outlook

Market Size

TABLE 33 GLOBAL SALES OF THYROID HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)

FIGURE 15 WORLDWIDE SALES OF THYROID HORMONE THERAPY, 2006-2013 ($ MILLIONS)

TESTOSTERONE HORMONE THERAPY

Market Outlook

Market Size

TABLE 34 GLOBAL SALES OF TESTOSTERONE HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)

FIGURE 16 WORLDWIDE SALES OF TESTOSTERONE HORMONE THERAPY, 2006-2013 ($ MILLIONS)

ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)

Market Outlook

Market Size

TABLE 35 GLOBAL SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECPTOR MODULATORS, THROUGH 2013 ($MILLIONS)

FIGURE 17 WORLDWIDE SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2006-2013 ($MILLIONS)

ANTIANDROGEN THERAPY

Market Outlook

Market Size

TABLE 36 GLOBAL SALES OF ANTIANDROGEN THERAPY, THROUGH 2013 ($ MILLIONS)

FIGURE 18 WORLDWIDE SALES OF ANTIANDROGEN THERAPY,2006-2013 ($ MILLIONS)

AROMATASE INHIBITORS

Market Outlook

Market Size

TABLE 37 GLOBAL SALES OF AROMATASE INHIBITORS,THROUGH 2013 ($ MILLIONS)

FIGURE 19 WORLDWIDE SALES OF AROMATASE INHIBITORS,2006-2013 ($ MILLIONS)

LUTEINIZING HORMONE-RELEASING HORMONE (LH RH)

AGONISTS

Market Outlook

Market Size

TABLE 38 GLOBAL SALES OF LH RH AGONISTS, THROUGH 2013 ($ MILLIONS)

FIGURE 20 WORLDWIDE SALES OF LH RH AGONIST, 2006-2013 ($ MILLIONS)

New Developments

TABLE 39 CLINICAL TRIALS IN THE ESTROGEN REPLACEMENT THERAPY

TABLE 40 CLINICAL TRIALS IN THE PROGESTEROEN THERAPY

TABLE 41 CLINICAL TRIALS IN THYROID HORMONE THERAPY

TABLE 42 CLINICAL TRIALS IN TESTOSTERONE REPLACEMENT THERAPY

TABLE 43 CLINICAL TRIALS IN RECOMBINANT GROWTH HORMONE

TABLE 44 CLINICAL TRIALS IN ANTIESTROGEN THERAPY

TABLE 45 CLINICAL TRIALS IN ESTROGEN RECEPTOR MODULATORS

TABLE 46 CLINICAL TRIALS IN ANTIANDROGEN THERAPY

TABLE 47 CLINICAL TRIALS IN AROMATASE INHIBITORS

TABLE 48 CLINICAL TRIALS IN LH RH AGONISTS

CHAPTER TEN: MARKET BY DISEASE TYPE

TABLE 49 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF DISEASE, THROUGH 2013 ($ MILLIONS)

FIGURE 21 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF DISEASE, 2006-2013 ($ MILLIONS)

TABLE 50 MARKET SHARE OF VARIOUS TYPES OF DISEASES, 2007 (%)

FIGURE 22 MARKET SHARE OF VARIOUS TYPES OF DISEASES, 2007 (%)

MENOPAUSE

TABLE 51 GLOBAL SALES OF HRT IN MENOPAUSE MARKET, THROUGH 2013 ($ MILLIONS)

FIGURE 23 GLOBAL SALES OF HRT IN MENOPAUSE MARKET, 2006-2013 ($ MILLIONS)

OSTEOPOROSIS

TABLE 52 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, THROUGH 2013 ($ MILLIONS)

FIGURE 24 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, 2006-2013 ($ MILLIONS)

HYPOTHYROIDISM

TABLE 53 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, THROUGH 2013 ($ MILLIONS)

FIGURE 25 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, 2006-2013 ($ MILLIONS)

MALE HYPOGONADISM

TABLE 54 GLOBAL SALES OF HRT IN THE MALE HYPOGONADISM MARKET, THROUGH 2013 ($ MILLIONS)

FIGURE 26 GLOBAL SALES OF HRT IN THE MALE HYPOGINADISM MARKET, 2006-2013 ($ MILLIONS)

KLINEFELTER SYNDROME

TABLE 55 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, THROUGH 2013 ($ MILLIONS)

FIGURE 27 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, 2006-2013 ($ MILLIONS)

TURNER’S SYNDROME

TABLE 56 GLOBAL SALES OF HRT IN TURNER’S SYNDROME MARKET, THROUGH 2013 ($ MILLIONS)

FIGURE 28 GLOBAL SALES OF HRT IN TURNER’S SYNDROME MARKET, 2006-2013 ($ MILLIONS)

GROWTH HORMONE DEFICIENCY

TABLE 57 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFICIENCY MARKET, THROUGH 2013 ($ MILLIONS)

FIGURE 29 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFECIENCY MARKET, 2006-2013 ($ MILLIONS)

CANCER

TABLE 58 GLOBAL SALES OF HRT IN CANCER MARKE, THROUGH 2013 ($ MILLIONS)

FIGURE 30 GLOBAL SALES OF HRT IN CANCER MARKET, 2006-2013 ($ MILLIONS)

CHAPTER ELEVEN: PATENT ANALYSIS

TOTAL PATENTS

PATENTS BY YEAR

TABLE 59 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2008

FIGURE 31 NUMBER OF PATENTS, 2005-2008

PATENTS BY TYPE

TABLE 60 NUMBER OF PATENTS BY TYPE, 2005-2008

FIGURE 32 NUMBER OF PATENTS BY TYPE, 2005-2008

FIGURE 33 NUMBER OF PATENTS, SHARE BY TYPE OF HORMONE, 2005-2008 (%)

FIGURE 33 ()

PATENTS BY COUNTRY

TABLE 61 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008

FIGURE 34 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008

PATENTS BY COMPANY

TABLE 62 NUMBER OF PATENTS BY COMPANY, 2005-2008

FIGURE 35 NUMBER OF PATENTS BY COMPANY, 2005-2008

PATENTS BY ASSIGNEE

TABLE 63 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2005-2008

FIGURE 36 NUMBER OF PATENTS BY ASSIGNEE, 2005-2008

CHAPTER TWELVE: CURRENT AND FUTURE HORMONE REPLACEMENT THERAPY AND “OTHER” HORMONE THERAPY MARKET

TABLE 64 LEADING BRANDED DRUGS IN VARIOUS HORMONE THERAPIES

CURRENT AND FUTURE HORMONE…()

CHAPTER THIRTEEN: COMPANY PROFILES

ABBOTT LABORATORIES INC

ACRUX LIMITED

ASCEND THERAPEUTICS

ASTRAZENECA PLC

AUXILIUM PHARMACEUTICALS, INC

BARR PHARMACEUTICALS, INC.

BAYER SCHERING PHARMA AG

BIOSANTE PHARMACEUTICALS

CANGENE CORPORATION

COLUMBIA LABORATORIES, INC.

ELI LILLY & CO

EMD SERONO, INC

FERRING PHARMACEUTICALS

GALEN LTD

GENENTECH

GENESCIENCE PHARMACEUTICALS INC

IMPAX LABORATORIES, INC

INDEVUS PHARMECEUTICALS, INC

IPSEN SA

JHP PHARMACEUTICALS

KING PHARMACEUTICALS, INC.

KV PHARMACEUTICALS

MYLAN, INC

NOVARTIS

NOVO NORDISK

NYCOMED U.S

ORION CORPORATION

PADDOCK LABORATORIES, INC.

PAR PHARMACEUTICAL COMPANIES, INC.

PFIZER INC

SANOFI AVENTIS

SOLVAY PHARMACEUTICALS

SYNERX PHARMA

UNIGENE LABORATORIES, INC

UNIMED PHARMACEUTICALS, INC.

WARNER CHILCOTT

WATSON LABS

WYETH

APPENDIX

ABBREVIATIONS

TABLE 1 ANATOMICAL CLASSIFICATION OF HORMONES

TABLE 2 CHEMICAL CLASSIFICATION OF HORMONES

TABLE 3 DRUG PRODUCTS USED IN ESTROGEN THERAPY

TABLE 4 DRUG PRODUCTS USED IN ESTROGEN/PROGESTERONE COMBINATION THERAPY

TABLE 5 DRUG PRODUCTS USED IN PROGESTERONE THERAPY

TABLE 6 DRUG PRODUCTS USED IN RECOMBINANT GROWTH HORMONES

TABLE 7 DRUG PRODUCTS USED IN THYROID HORMONE THERAPY

TABLE 8 DRUG PRODUCTS USED IN TESTOSTERONE REPLACEMENT THERAPY

TABLE 9 DRUG PRODUCTS USED IN SELECTIVE ESTROGEN RECEPTOR MODULATORS

TABLE 10 DRUG PRODUCTS USED IN ANTIESTROGENS

TABLE 11 DRUG PRODUCTS USED IN ANTIANDROGEN THERAPY

TABLE 12 DRUG PRODUCTS USED IN AROMATASE INHIBITOR THERAPY

TABLE 13 DRUG PRODUCTS USED AS LUTEINIZING HORMONERELEASING HORMONE (LH RH)

TABLE 14 HORMONE THERAPY DRUGS APPROVED BY FDA (2005 TO JUNE 2008)

TABLE 15 HORMONE THERAPY ALL TYPES OF APPROVALS BY FDA (2005 TO JUNE 2008)

TABLE 16 NEW DRUG APPLICATIONS (2005 TO JUNE 2008)

TABLE 17 RECALLS AND SAFETY ALERTS (2005 TO JUNE 2008)

TABLE 18 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN (ALONE) THERAPY, 2007 (%)

TABLE 19 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/ PROGESTERONE) THERAPY, 2007 (%)

TABLE 20 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%)

TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%)

TABLE 22 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%)

TABLE 23 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%)

TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)

TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)

TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)

TABLE 27 SIGNIFICANT PATENT EXPIRIES

TABLE 28 WORLDWIDE SALES OF HORMONE THERAPIES, THROUGH 2013 ($ MILLIONS)

TABLE 29 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007

TABLE 30 GLOBAL SALES OF ESTROGEN (ALONE) THERAPY, THROUGH 2013 ($ MILLIONS)

TABLE 31 GLOBAL SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), THROUGH 2013 ($ MILLIONS)

TABLE 32 GLOBAL SALES OF RECOBINANT GROWTH HORMONE THERAPY THROUGH 2013 ($ MILLIONS)

TABLE 33 GLOBAL SALES OF THYROID HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)

TABLE 34 GLOBAL SALES OF TESTOSTERONE HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)

TABLE 35 GLOBAL SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECPTOR MODULATORS, THROUGH 2013 ($ MILLIONS)

TABLE 36 GLOBAL SALES OF ANTIANDROGEN THERAPY, THROUGH 2013 ($ MILLIONS)

TABLE 37 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 ($ MILLIONS)